Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Regeneron is studying its antibody treatment in four different patient groups. Photo: Regeneron
Regeneron Pharmaceuticals is testing a new coronavirus antibody drug in humans as part of a federally funded, wide-ranging, placebo-controlled clinical trial.
Why it matters: The drug candidate is going to be tested as a way to both treat and prevent the infection.
Details: Regeneron is testing its "antibody cocktail" in four patient groups, according to the company's announcement:
- "Hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as health care workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate)."
Between the lines: Regeneron has had some success with this idea of combining antibodies into one treatment as a way to ward off invading diseases — most recently with a treatment for the Ebola virus.
- Eli Lilly similarly is testing its own coronavirus antibody treatment and hopes to get emergency authorization by the fall, Reuters reported.
Yes, but: This is still just the beginning of a phase one trial. We're several months away from knowing whether these treatments are safe and effective against the virus and disease.